Inari Medical, Inc. – NASDAQ:NARI

Add to watchlist

$79.978

+27.00

+50.99%

Market closed

Open in 1 day

-2.65%

month

-2.65%

quarter

-19.50%

year

Market Cap	3.15B
Enterprise value	3.50B

P/E	-111.54
EV/Sales	9.12
EV/EBITDA	-186.45
Price/Sales	9.20
Price/Book	8.46
PEG ratio	0.29
EPS	-0.40

Revenue	520.65M
EBITDA	11.26M
Income	-23.62M
Revenue Q/Q	23.26%
Revenue Y/Y	26.10%

Profit margin	-7.63%
Oper. margin	-7.33%
Gross margin	88.39%
EBIT margin	-7.33%
EBITDA margin	2.16%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Inari Medical Stock Forecast

M Q Y

Last Year

$64

Potential downside: -19.97%

Analysts Price target
Financials & Ratios estimates

Inari Medical, Inc. (NASDAQ:NARI): Profit margin
Jun 2023	119.00M	2.08M	1.75%
Sep 2023	126.36M	3.16M	2.5%
Dec 2023	132.09M	-4.66M	-3.53%
Mar 2024	143.19M	-24.20M	-16.9%

Inari Medical, Inc. (NASDAQ:NARI): Earnings per share (EPS)
2024-02-28	-0.00375	0.05

Inari Medical, Inc. (NASDAQ:NARI): Debt to assets
Jun 2023	524968000	89.32M	17.01%
Sep 2023	548835000	96.69M	17.62%
Dec 2023	674235000	209.32M	31.05%
Mar 2024	661776000	214.54M	32.42%

Inari Medical, Inc. (NASDAQ:NARI): Cash Flow
Jun 2023	9.76M	-6.08M	-2.35M
Sep 2023	15.93M	11.82M	3.46M
Dec 2023	12.24M	-59.71M	-2.41M
Mar 2024	-12.28M	39.16M	1.01M

Inari Medical alternative data

Inari Medical
Employees

Inari Medical, Inc. (NASDAQ:NARI): Employee count
Aug 2023	1,100
Sep 2023	1,100
Oct 2023	1,100
Nov 2023	1,100
Dec 2023	1,100
Jan 2024	1,100
Feb 2024	1,100
Mar 2024	1,300
Apr 2024	1,300
May 2024	1,300
Jun 2024	1,300
Jul 2024	1,300

Inari Medical
Hedge Funds Holdings Q3 2022

76.75% -10.95%

of NARI is owned by hedge funds

217 -3

hedge funds hold NARI stock

40.81M -3.87M

shares is hold by hedge funds

NARI hedge funds holdings changes

Inari Medical, Inc. (NASDAQ:NARI): Insider trades (number of shares)
Period	Buy	Sel
May 2021	0	114000
Jun 2021	0	73000
Jul 2021	0	242085
Aug 2021	0	56000
Sep 2021	0	56000
Oct 2021	0	156000
Nov 2021	0	47000
Dec 2021	0	109222
Jan 2022	0	42500
Feb 2022	0	66802
Mar 2022	0	90198
Apr 2022	0	40000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	5 Apr 2022	HOFFMAN WILLIAM director, officer..	Stock Options (Right to buy)	30,000	$0.43	$12,840
Sale	5 Apr 2022	HOFFMAN WILLIAM director, officer..	Common Stock	20,080	$90.63	$1,819,850
Sale	5 Apr 2022	HOFFMAN WILLIAM director, officer..	Common Stock	7,149	$89.77	$641,766
Sale	5 Apr 2022	HOFFMAN WILLIAM director, officer..	Common Stock	2,771	$88.78	$246,009
Option	5 Apr 2022	HOFFMAN WILLIAM director, officer..	Common Stock	30,000	$0.43	$12,840
Sale	1 Apr 2022	HYKES ANDREW officer: Chief Op..	Common Stock	1,606	$92.1	$147,913
Sale	1 Apr 2022	HYKES ANDREW officer: Chief Op..	Common Stock	3,394	$91.63	$310,992
Sale	1 Apr 2022	HYKES ANDREW officer: Chief Op..	Common Stock	1,373	$91.86	$126,124
Sale	1 Apr 2022	HYKES ANDREW officer: Chief Op..	Common Stock	1,020	$90.73	$92,545
Sale	1 Apr 2022	HYKES ANDREW officer: Chief Op..	Common Stock	2,607	$89.76	$234,004

Status	Patent	Filling date	Issue date
Application	Application SINGLE INSERTION DELIVERY SYSTEM FOR TREATING EMBOLISM AND ASSOCIATED SYSTEMS AND METHODS Filling date: 11 Oct 2021 Issue date: 4 Aug 2022	11 Oct 2021	4 Aug 2022
Application	Application HEMOSTASIS VALVES AND METHODS OF USE Filling date: 25 Mar 2022 Issue date: 7 Jul 2022	25 Mar 2022	7 Jul 2022
Application	Application DEVICE AND METHOD FOR TREATING VASCULAR OCCLUSION Filling date: 25 Mar 2022 Issue date: 7 Jul 2022	25 Mar 2022	7 Jul 2022
Application	Application METHOD FOR TREATING VASCULAR OCCLUSION Filling date: 11 Feb 2022 Issue date: 26 May 2022	11 Feb 2022	26 May 2022
Application	Application METHOD FOR TREATING VASCULAR OCCLUSION Filling date: 11 Feb 2022 Issue date: 26 May 2022	11 Feb 2022	26 May 2022
Application	Application CATHETERS HAVING SHAPED DISTAL PORTIONS, AND ASSOCIATED SYSTEMS AND METHODS Filling date: 17 Nov 2021 Issue date: 19 May 2022	17 Nov 2021	19 May 2022
Application	Application DEVICES FOR ADJUSTABLY TENSIONING SUTURES, AND ASSOCIATED SYSTEMS AND METHODS Filling date: 10 Nov 2021 Issue date: 12 May 2022	10 Nov 2021	12 May 2022
Application	Application AUTOMATICALLY-LOCKING VACUUM SYRINGES, AND ASSOCIATED SYSTEMS AND METHODS Filling date: 6 Aug 2021 Issue date: 10 Feb 2022	6 Aug 2021	10 Feb 2022
Application	Application METHODS AND APPARATUS FOR TREATING EMBOLISM Filling date: 24 Jun 2021 Issue date: 27 Jan 2022	24 Jun 2021	27 Jan 2022
Application	Application INTRAVASCULAR TREATMENT OF VASCULAR OCCLUSION AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS Filling date: 29 Jun 2021 Issue date: 20 Jan 2022	29 Jun 2021	20 Jan 2022

Inari Medical
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 30 Apr 2024	Q1 2024 Earnings Call Transcript
Q4 2023 28 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 1 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 2 Aug 2023	Q2 2023 Earnings Call Transcript

NARI earnings call transcripts

Inari Medical
Executives

Insider	Age	Compensation
Mr. William H. Hoffman (1967) Chief Executive Officer, Pres & Director	58	$1,130,000
Dr. Thomas M. Tu M.D. (1973) Chief Medical Officer	52	$904,220
Mr. Andrew J. Hykes (1973) Chief Operating Officer	52	$721,280

Inari Medical
Latest News

Sunday, 29 December 2024
10:00	Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Inari Medical, Inc. (NARI) And Encourages Stockholders to Reach Out	accesswire.com
Tuesday, 24 December 2024
10:00	Bronstein, Gewirtz & Grossman, LLC Is Investigating Inari Medical, Inc. (NARI) And Encourages Stockholders to Connect	accesswire.com
Sunday, 22 December 2024
10:00	Inari Medical, Inc. (NARI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation	accesswire.com
Wednesday, 18 December 2024
10:00	Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Inari Medical, Inc. (NARI) and Encourages Stockholders to Learn More About the Investigation	accesswire.com
Sunday, 15 December 2024
10:00	Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Investors to Inquire about Securities Investigation	accesswire.com
Thursday, 12 December 2024
17:45	NARI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Inari Medical, Inc. and Encourages Investors to Contact the Firm	accesswire.com
Wednesday, 4 December 2024
08:51	Reasons to Retain Inari Medical Stock in Your Portfolio for Now	zacks.com
Tuesday, 3 December 2024
12:21	NARI Stock Likely to Gain Following Reimbursement Approval in Japan	zacks.com
Monday, 2 December 2024
16:06	Inari Medical Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan and New Distribution Partnership with Medikit Co., Ltd.	globenewswire.com
16:05	Inari Medical Announces Joint Venture in Greater China	globenewswire.com
Tuesday, 29 October 2024
11:56	PEERLESS Results Show Superiority of FlowTriever® Compared to Catheter-Directed Thrombolytics for Intermediate-Risk Pulmonary Embolism	globenewswire.com
11:31	Inari Medical Q3 Earnings Miss Estimates, Revenues Increase Y/Y	zacks.com
Monday, 28 October 2024
20:16	Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Transcript	seekingalpha.com
18:56	Inari Medical, Inc. (NARI) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
16:05	Inari Medical Reports Third Quarter 2024 Financial Results	globenewswire.com
Monday, 21 October 2024
13:00	Okami Medical Announces Closing Of $32.5M Financing	prnewswire.com
11:05	Analysts Estimate Inari Medical, Inc. (NARI) to Report a Decline in Earnings: What to Look Out for	zacks.com
Monday, 7 October 2024
16:06	Inari Medical to Host Analyst and Investor Meeting Following PEERLESS RCT Presentation	globenewswire.com
16:05	Inari Medical to Announce Third Quarter 2024 Financial Results	globenewswire.com
Wednesday, 2 October 2024
12:11	Inari Medical Inc (NARI) Shares Up 3.22% on Oct 2	gurufocus.com
Friday, 13 September 2024
09:26	Reasons to Retain Inari Medical Stock in Your Portfolio for Now	zacks.com
Thursday, 29 August 2024
16:05	Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024	globenewswire.com
Monday, 26 August 2024
12:35	Inari Medical (NARI) Issues Notice Post ClotTriever XL Recall	zacks.com
Wednesday, 21 August 2024
16:05	Inari Medical to Present at Upcoming Investor Conferences	globenewswire.com
Wednesday, 31 July 2024
14:30	7 Leading MedTech Stocks for Next-Gen Health Solutions	investorplace.com
13:11	Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y	zacks.com
Tuesday, 30 July 2024
21:53	Inari Medical, Inc. (NARI) Q2 2024 Earnings Call Transcript	seekingalpha.com
18:46	Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
16:10	Inari Medical Announces Chief Financial Officer Retirement and Succession Plan	globenewswire.com
Tuesday, 23 July 2024
11:06	Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release	zacks.com

Ideas & Opinions

Seeking Alpha 9 Apr 2024

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
Seeking Alpha 7 Nov 2023

Inari Medical: Top Buy For End Of 2023 And 2024
Seeking Alpha 31 Jul 2023

Inari Medical: Approaching Interesting Levels
Seeking Alpha 10 May 2023

Inari Medical: Targeting Underpenetrated $5.8 Billion Thromboembolism Market
Seeking Alpha 3 Mar 2023

Inari Medical: Reinvesting Heavily Into Growing International Markets
Seeking Alpha 29 Nov 2022

Inari Medical: Retain Buy, No Change To Targets Despite Flat Price Action
Seeking Alpha 7 Sep 2022

Inari Medical: Growth Set To Reaccelerate In The Back Half Of The Year
Seeking Alpha 18 Aug 2022

Sector Rerating Has Cast A Shadow Over Penumbra
Seeking Alpha 22 Jul 2022

Inari Medical: Fundamentals Soft, Technicals Supportive Of Near-Term Upside Capture
Seeking Alpha 1 Mar 2022

Penumbra A Little Beaten Down Despite Strong Growth Opportunities

Frequently Asked Questions (FAQ)

What's the price of Inari Medical stock today?

One share of Inari Medical stock can currently be purchased for approximately $79.98.
When is Inari Medical's next earnings date?

Unfortunately, Inari Medical's (NARI) next earnings date is currently unknown.
Does Inari Medical pay dividends?

No, Inari Medical does not pay dividends.
How much money does Inari Medical make?

Inari Medical has a market capitalization of 3.15B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 28.73% to 493.63M US dollars. Inari Medical made a loss 1.64M US dollars in net income (profit) last year or $0.05 on an earnings per share basis.
What is Inari Medical's stock symbol?

Inari Medical, Inc. is traded on the NASDAQ under the ticker symbol "NARI".
What is Inari Medical's primary industry?

Company operates in the Healthcare sector and Medical - Devices industry.
How do i buy shares of Inari Medical?

Shares of Inari Medical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Inari Medical's key executives?
Inari Medical's management team includes the following people:
- Mr. William H. Hoffman Chief Executive Officer, Pres & Director(age: 58, pay: $1,130,000)
- Dr. Thomas M. Tu M.D. Chief Medical Officer(age: 52, pay: $904,220)
- Mr. Andrew J. Hykes Chief Operating Officer(age: 52, pay: $721,280)
How many employees does Inari Medical have?

As Jul 2024, Inari Medical employs 1,300 workers.
When Inari Medical went public?

Inari Medical, Inc. is publicly traded company for more then 5 years since IPO on 22 May 2020.
What is Inari Medical's official website?

The official website for Inari Medical is inarimedical.com.
Where are Inari Medical's headquarters?

Inari Medical is headquartered at 6001 Oak Canyon, Irvine, CA.
How can i contact Inari Medical?

Inari Medical's mailing address is 6001 Oak Canyon, Irvine, CA and company can be reached via phone at 877 923 4747.
What is Inari Medical stock forecast & price target?

Based on 8 Wall Street analysts` predicted price targets for Inari Medical in the last 12 months, the avarage price target is $64. The average price target represents a -19.97% change from the last price of $79.98.

Inari Medical, Inc.

inarimedical.com

Exchange:

NASDAQ

Full time employees:

1,300

Industry:

Medical - Devices

Sector:

Healthcare

Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

877 923 4747

6001 Oak Canyon
Irvine, CA 92618

CIK: 0001531048
ISIN: US45332Y1091
CUSIP: 45332Y109